Myelodysplastic Syndromes — Lower-Risk (IPSS-R very low / low / intermediate) · Luspatercept (MDS-LR with RS or post-ESA failure)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | aggressive |
|---|---|
| Linked regimen | REG-LUSPATERCEPT-MDS-LR |
| ID | IND-MDS-LR-1L-LUSPATERCEPT |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-MDS-LR |
| Sources | SRC-COMMANDS-FENAUX-2020 SRC-ESMO-MDS-2021 SRC-NCCN-AML-2025 |
Notes
Aggressive track for MDS-LR. NOT registered in Ukraine — currently aspirational pathway; ESA remains practical 1L. STUB — requires clinical co-lead signoff.
Used By
Algorithms
ALGO-MDS-LR-1L- ALGO-MDS-LR-1LALGO-MDS-LR-2L- ALGO-MDS-LR-2L